Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Operating income | -$16.6M | -$18.7M | -$8.12M | -$5.81M | -$9.77M | -$19.3M | -$10.6M | -$7.30M | — | -$122M |
| Net income | -$16.4M | -$18.5M | -$7.93M | -$5.48M | -$9.74M | -$19.3M | -$9.93M | -$5.34M | — | -$105M |
| EPS (diluted) | -$1.81 | -$1.77 | -$10.31 | -$4.15 | -$2.07 | -$1.39 | -$0.69 | -$0.37 | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.0M | -$17.5M | -$8.24M | -$4.80M | -$7.72M | -$18.8M | -$10.9M | -$5.01M | — | -$88.2M |
| Capital expenditures | $12.0K | $3.00K | $4.00K | $4.00K | $19.0K | $43.0K | $2.00K | $0.00 | — | $209K |
| Free cash flow | -$15.0M | -$17.5M | -$8.25M | -$4.80M | -$7.74M | -$18.8M | -$10.9M | -$5.01M | — | -$88.4M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $7.40M | $8.70M | $6.61M | $8.36M | $49.1M | $53.4M | $42.4M | $37.4M | $61.6M | $46.9M |
| Total assets | $24.6M | $12.4M | $6.83M | $8.54M | $50.4M | $54.9M | $43.1M | $37.9M | $396M | $489M |
| Total liabilities | $2.44M | $2.09M | $793K | $926K | $3.91M | $3.88M | $1.41M | $841K | $13.8M | $16.7M |
| Shareholders' equity | $22.2M | $10.3M | $6.03M | $7.61M | $46.5M | $51.0M | $41.7M | $37.0M | $1.00K | $472M |
| Retained earnings | -$113M | -$131M | -$139M | -$144M | -$154M | -$173M | -$183M | -$189M | -$83.7M | -$189M |
| Shares (wtd avg diluted) | 9.08M | 11.8M | 774K | 1.59M | 9.55M | 14.4M | 14.4M | 14.5M | 37.4M | 48.7M |
Every figure is extracted from Oruka Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.